AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18653484 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 355
Study 18653484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Licofelone and Naproxen
Number of subjects: 355
Study 17561796 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Group (integrated glucose meters and electronic logbooks)
Number of subjects: 205
Study 17561796 — intervention group
Group type: COMPARATOR
Intervention: Paper Group (conventional meters and paper logbooks)
Number of subjects: 205
Study 17561796 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated meters/logbooks (continued use)
Number of subjects: 205
Study 17561796 — intervention group
Group type: COMPARATOR
Intervention: Conventional meters/logbooks (continued use or switching)
Number of subjects: 205
Study 14700144 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 per cent sulfur ointment
Number of subjects: 100
Study 14700144 — intervention group
Group type: COMPARATOR
Intervention: 0.3 per cent gamma benzene hexachloride gel
Number of subjects: 100
Study 10975210 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 52
Study 10975210 — intervention group
Group type: COMPARATOR
Intervention: Animal insulin
Number of subjects: 52
Study 8865523 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VII:C levels
Number of subjects: 270
Study 8865523 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype, body mass index, cholesterol, triglycerides, gender
Number of subjects: 270
Study 8865523 — intervention group
Group type: COMPARATOR
Intervention: Severity of atheroma
Number of subjects: 270
Study 8865523 — intervention group
Group type: COMPARATOR
Intervention: History of myocardial infarction
Number of subjects: 270
Study 8865523 — intervention group
Group type: COMPARATOR
Intervention: Genotype-environment interaction
Number of subjects: 270
Study 1632401 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor
Number of subjects: 6273
Study 1632401 — intervention group
Group type: COMPARATOR
Intervention: Registry data collection
Number of subjects: 6273
Study 6431586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 31
Study 6431586 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 31
Study 31246588 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 200
Study 31246588 — intervention group
Group type: COMPARATOR
Intervention: Sham PCI
Number of subjects: 200
Study 31246588 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 200
Study 28538079 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening during LEEP
Number of subjects: 150
Study 28538079 — intervention group
Group type: COMPARATOR
Intervention: Control (no music) during LEEP
Number of subjects: 150
Study 25359382 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7.5 mg daily from W7)
Number of subjects: 400
Study 25359382 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA Slim (MTX+30 mg prednisone tapered to 5 mg from W6)
Number of subjects: 400
Study 25359382 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA Avant-Garde (MTX+leflunomide+30 mg prednisone tapered to 5 mg from W6)
Number of subjects: 400
Study 23526739 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMS P3F+
Number of subjects: 434
Study 23526739 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMS P7F+
Number of subjects: 434
Study 23526739 — intervention group
Group type: EXPERIMENTAL
Intervention: ERMS
Number of subjects: 434
Study 23526739 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMSn (without detectable fusion)
Number of subjects: 434
Study 23526739 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMSn
Number of subjects: 434
Study 21810636 — intervention group
Group type: EXPERIMENTAL
Intervention: Air cleaners only
Number of subjects: 126
Study 21810636 — intervention group
Group type: EXPERIMENTAL
Intervention: Air cleaners plus health coach
Number of subjects: 126
Study 21810636 — intervention group
Group type: COMPARATOR
Intervention: Delayed air cleaner (control)
Number of subjects: 126
Study 19152024 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention (18-min duration)
Number of subjects: 196
Study 19152024 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 196
Study 19152024 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 196
Study 17092365 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat-fibre
Number of subjects: 14
Study 17092365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-fibre
Number of subjects: 14
Study 17092365 — intervention group
Group type: COMPARATOR
Intervention: Control (white bread)
Number of subjects: 14
Study 17092365 — intervention group
Group type: EXPERIMENTAL
Intervention: All test meals
Number of subjects: 14
Study 14979845 — intervention group
Group type: EXPERIMENTAL
Intervention: Paquin School Program
Number of subjects: 877
Study 14979845 — intervention group
Group type: COMPARATOR
Intervention: Comparison schools
Number of subjects: 877
Study 10912846 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (1-34) 400 IU/day
Number of subjects: 49
Study 10912846 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 9310875 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDOGAIN
Number of subjects: 107
Study 9310875 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery without EMDOGAIN
Number of subjects: 107
Study 8104978 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily skin preparation with 10% aqueous povidone-iodine for 48 h preoperatively (Group A, N = 34)
Number of subjects: 64
Study 8104978 — intervention group
Group type: COMPARATOR
Intervention: No skin preparation (Group B, N = 30)
Number of subjects: 64
Study 3516177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin sodium/amoxicillin trihydrate therapy
Number of subjects: 0
Study 3516177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31054010 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Symprove™, 1 ml/kg/day for 4 weeks)
Number of subjects: 142
Study 31054010 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Symprove™)
Number of subjects: 142
Study 31054010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 28129288 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 100
Study 25923274 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic otitis media and cholesteatoma patients (n=51)
Number of subjects: 51
Study 25923274 — intervention group
Group type: COMPARATOR
Intervention: Chronic otitis media without cholesteatoma patients (control group, n=30)
Number of subjects: 51
Study 25923274 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (n=51)
Number of subjects: 51
Study 23506314 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape seed oil (GSO)
Number of subjects: 44
Study 23506314 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SFO)
Number of subjects: 44
Study 21372193 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 76
Study 21372193 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 76
Study 18207598 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose daily cisplatin
Number of subjects: 0
Study 18207598 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy (77Gy in 70 fractions in 35 treatment days)
Number of subjects: 0
Study 16810109 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine/didanosine
Number of subjects: 980
Study 16810109 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine/lamivudine with nelfinavir, efavirenz, or both
Number of subjects: 980
Study 16810109 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation
Number of subjects: 980
Study 16810109 — intervention group
Group type: EXPERIMENTAL
Intervention: Virologic suppression (VS)
Number of subjects: 980
Study 16810109 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent T-cell activation
Number of subjects: 980
Study 12716243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 212
Study 12716243 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 212
Study 11072770 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim/Bike trial (SB) - 3000 m swimming followed by 3-h cycling
Number of subjects: 8
Study 11072770 — intervention group
Group type: COMPARATOR
Intervention: Control trial (CON) - 3-h cycling without prior swimming
Number of subjects: 8
Study 9171065 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (80 mg in 8 ml of isotonic saline)
Number of subjects: 158
Study 9171065 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (1 ml)
Number of subjects: 158
Study 7584257 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar target events
Number of subjects: 0
Study 7584257 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinctive target events relative to local context
Number of subjects: 0
Study 7584257 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect retrospective memory task (word fragment completion)
Number of subjects: 0
Study 7584257 — intervention group
Group type: COMPARATOR
Intervention: Explicit retrospective memory tasks (recall and recognition)
Number of subjects: 0
Study 2957500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine bilateral infiltration beneath the site of ring application
Number of subjects: 200
Study 31959707 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOA)
Number of subjects: 221
Study 31959707 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKA)
Number of subjects: 221
Study 29439718 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12v2® health survey
Number of subjects: 1587
Study 28272343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Food Record (mFR) application
Number of subjects: 285
Study 28272343 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥ 25
Number of subjects: 285
Study 25641635 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU
Number of subjects: 69
Study 25641635 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 69
Study 23774797 — intervention group
Group type: EXPERIMENTAL
Intervention: LDA 100 mg (regimen A)
Number of subjects: 215
Study 23774797 — intervention group
Group type: EXPERIMENTAL
Intervention: LDA/clopidogrel (regimen AC)
Number of subjects: 215
Study 23774797 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg (regimen C)
Number of subjects: 215
Study 23774797 — intervention group
Group type: EXPERIMENTAL
Intervention: LDA with rabeprazole 10 mg (regimen AC)
Number of subjects: 215
Study 23774797 — intervention group
Group type: COMPARATOR
Intervention: Non-LDA subjects (control group in study 1)
Number of subjects: 215
Study 20853136 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel PCI (MV PCI)
Number of subjects: 31224
Study 20853136 — intervention group
Group type: COMPARATOR
Intervention: Culprit only revascularization (COR)
Number of subjects: 31224
Study 18777556 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol/kg of Gd-DTPA
Number of subjects: 12
Study 18777556 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg of Gd-DTPA
Number of subjects: 12
Study 16571279 — intervention group
Group type: EXPERIMENTAL
Intervention: Taizhi'an capsule (TZA) 0.9 g 3 times a day + Simvastatin (Sim) 10 mg at bedtime
Number of subjects: 80
Study 16571279 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (Sim) 20 mg at bedtime
Number of subjects: 80
Study 14570719 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 750 mg twice daily
Number of subjects: 31
Study 14570719 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 31
Study 14570719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10889426 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic capture technique
Number of subjects: 40
Study 10889426 — intervention group
Group type: COMPARATOR
Intervention: Non-capture technique
Number of subjects: 40
Study 7750187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated oestrogens (OCE, 0.625 mg) + Medroxyprogesterone acetate (MPA, 5 mg)
Number of subjects: 43
Study 7750187 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (TE, 50 micrograms) + Medroxyprogesterone acetate (MPA, 5 mg)
Number of subjects: 43
Study 7750187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 43
Study 2212918 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1 g daily for 7 days
Number of subjects: 171
Study 2212918 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole 2 g single dose
Number of subjects: 171
Study 495848 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative cephaloridine
Number of subjects: 107
Study 495848 — intervention group
Group type: COMPARATOR
Intervention: No cephaloridine
Number of subjects: 107
Study 31769240 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Degludec/Insulin Aspart (IDegAsp)
Number of subjects: 59
Study 31769240 — intervention group
Group type: COMPARATOR
Intervention: Basal Insulin
Number of subjects: 59
Study 31417681 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelmeg (Test)
Number of subjects: 96
Study 31417681 — intervention group
Group type: COMPARATOR
Intervention: Neulasta (Reference)
Number of subjects: 96
Study 27756182 — intervention group
Group type: EXPERIMENTAL
Intervention: Theaflavin (50 or 100 mg/day)
Number of subjects: 30
Study 27756182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27756182 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin (400 mg/ml)
Number of subjects: 30
Study 25932526 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic (EM) guidance
Number of subjects: 18
Study 25932526 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 18
Study 22788780 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT CARE intervention
Number of subjects: 179
Study 22788780 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 179
Study 21507997 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting group curriculum program targeting young children's disruptive behaviors
Number of subjects: 39
Study 18489576 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine + Fluoride varnish (Group 3)
Number of subjects: 80
Study 18489576 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine varnish (Group 1)
Number of subjects: 80
Study 18489576 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (Group 2)
Number of subjects: 80
Study 18489576 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 4)
Number of subjects: 80
Study 16638862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-2
Number of subjects: 64
Study 16638862 — intervention group
Group type: COMPARATOR
Intervention: Low-dose IL-2
Number of subjects: 64
Study 16638862 — intervention group
Group type: COMPARATOR
Intervention: Concurrent high-dose IL-2
Number of subjects: 64
Study 16638862 — intervention group
Group type: COMPARATOR
Intervention: Recombinant vaccinia and fowlpox vaccines
Number of subjects: 64
Study 16638862 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment with IL-2
Number of subjects: 64
Study 12939169 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1240
Study 12939169 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1240
Study 11139091 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (surgery or angioplasty)
Number of subjects: 0
Study 11139091 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study 11139091 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 0
Study 9414363 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-handed users using their non-preferred hand
Number of subjects: 0
Study 9414363 — intervention group
Group type: COMPARATOR
Intervention: Right-handed users using their preferred hand
Number of subjects: 0
Study 8508692 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg oral ciprofloxacin administered 1, 2 or 3 hours before anesthesia
Number of subjects: 100
Study 8508692 — intervention group
Group type: COMPARATOR
Intervention: 80 mg gentamicin plus 500 mg metronidazole administered intravenously
Number of subjects: 100
Study 2433195 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisequens (Novo)
Number of subjects: 120
Study 2433195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequentially Dienestrol and Chlormadinon (Polfa)
Number of subjects: 120
Study 2433195 — intervention group
Group type: COMPARATOR
Intervention: No hormone therapy (control group)
Number of subjects: 120
Study 29169011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot yoga
Number of subjects: 14
Study 29169011 — intervention group
Group type: COMPARATOR
Intervention: Thermo-neutral yoga
Number of subjects: 14
Study 26792822 — intervention group
Group type: EXPERIMENTAL
Intervention: Model‐based iterative reconstruction (MBIR)
Number of subjects: 60
Study 26792822 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive statistical iterative reconstruction (ASIR)
Number of subjects: 60
Study 26792822 — intervention group
Group type: COMPARATOR
Intervention: Filtered back projection (FBP)
Number of subjects: 60
Study 25502128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-aware physicians (saw the cost of tests)
Number of subjects: 38
Study 25502128 — intervention group
Group type: COMPARATOR
Intervention: Cost-unaware physicians (did not see the cost of tests)
Number of subjects: 38
Study 22285278 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-standardized grass allergy immunotherapy tablet (Grazax)
Number of subjects: 238
Study 22285278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 20920198 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index Mark 3 (HUI3)
Number of subjects: 213
Study 20920198 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted associations
Number of subjects: 213
Study 18712620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release (SR) tablets of dextromethorphan hydrobromide
Number of subjects: 6
Study 18712620 — intervention group
Group type: COMPARATOR
Intervention: Immediate release tablets of dextromethorphan hydrobromide
Number of subjects: 6
Study 15968890 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 treatment for 18 days
Number of subjects: 2
Study 15968890 — intervention group
Group type: COMPARATOR
Intervention: Air for 9 days + CO2 for 9 days (control group)
Number of subjects: 2
Study 14629852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan exercise program (12 weeks, 3 times per week)
Number of subjects: 76
Study 10474465 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneurovascular transfer
Number of subjects: 30
Study 10474465 — intervention group
Group type: COMPARATOR
Intervention: Temporalis tendon transfer
Number of subjects: 30
Study 8538345 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser angioplasty
Number of subjects: 308
Study 8538345 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 308
Study 1351600 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbal therapy (TCHT)
Number of subjects: 40
Study 1351600 — intervention group
Group type: COMPARATOR
Intervention: Placebo herbs
Number of subjects: 40
Study 3880780 — intervention group
Group type: EXPERIMENTAL
Intervention: Terodiline
Number of subjects: 25
Study 3880780 — intervention group
Group type: EXPERIMENTAL
Intervention: Meladrazine
Number of subjects: 25
Study 3880780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terodiline and meladrazine
Number of subjects: 25
Study 31790452 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACPF + PBM
Number of subjects: 80
Study 31790452 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 80
Study 31790452 — intervention group
Group type: COMPARATOR
Intervention: CPP-ACPF
Number of subjects: 80
Study 31790452 — intervention group
Group type: COMPARATOR
Intervention: PBM
Number of subjects: 80
Study 29424447 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention programme consisting of 8 sessions, one per week, each lasting 90 minutes, run by a psychologist trained in behaviour analysis.
Number of subjects: 120
Study 29424447 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 120
Study 30634203 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenkang Injection (SI)
Number of subjects: 206
Study 30634203 — intervention group
Group type: COMPARATOR
Intervention: Rehydration therapy (normal saline)
Number of subjects: 206
Study 30634203 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose injection (control)
Number of subjects: 206
Study 23996496 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red blood cell (PRBC) transfusion
Number of subjects: 80
Study 23996496 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline levels of BDNF, sVCAM‐1, PDGF‐AA, t‐PAI‐1, and sICAM‐1
Number of subjects: 80
Study 23996496 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study 22704950 — intervention group
Group type: EXPERIMENTAL
Intervention: LA+RT- (Lymphadenectomy + Radiotherapy)
Number of subjects: 742
Study 22704950 — intervention group
Group type: EXPERIMENTAL
Intervention: RT (Radiotherapy)
Number of subjects: 742
Study 22704950 — intervention group
Group type: COMPARATOR
Intervention: LA-RT- (No Lymphadenectomy nor Radiotherapy)
Number of subjects: 742
Study 22704950 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-RT+ (Lymphadenectomy without Radiotherapy)
Number of subjects: 742
Study 22704950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LA and RT
Number of subjects: 742
Study 20158295 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect cue (speech preparation task)
Number of subjects: 175